Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-05

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

NCT02256631

HIV Infections

COMPLETED PHASE1

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

NCT05406583

HIV

COMPLETED PHASE1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255

HIV Infection

RECRUITING PHASE1/PHASE2

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

NCT00000952

HIV Infections

COMPLETED PHASE1

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

NCT01780831

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label, phase I study of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS administered soon after birth in infants exposed to HIV-1. The study is designed to assess the safety and pharmacokinetics (PK) profile of one and two subcutaneous (SC) doses of PGT121.414.LS alone or in combination with VRC07-523LS through Week 12 and Week 24, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 Stratum Formula Fed (FF)

Single subcutaneous (SC) dose of PGT121.414.LS at birth, based on weight.

Group Type EXPERIMENTAL

PGT121.414.LS

Intervention Type DRUG

Administered SC in the thigh

Cohort 1 Stratum Breastfed (BF)

Initial SC dose of PGT121.414.LS at birth, based on weight. Second SC dose of 100 mg PGT121.414.LS at Week 12, if still breastfeeding. Dosing at Week 12 is not based on weight.

Group Type EXPERIMENTAL

PGT121.414.LS

Intervention Type DRUG

Administered SC in the thigh

Cohort 2 Stratum FF

Single SC doses of PGT121.414.LS and VRC07-523LS at birth, based on weight.

Group Type EXPERIMENTAL

PGT121.414.LS

Intervention Type DRUG

Administered SC in the thigh

VRC07-523LS

Intervention Type DRUG

Administered SC in the thigh

Cohort 2 Stratum BF

Initial SC doses of PGT121.414.LS and VRC07-523LS at birth, based on weight. Second SC doses of 100 mg of PGT121.414.LS and 100 mg VRC07-523LS at Week 12, if still breastfeeding. Dosing at Week 12 is not based on weight.

Group Type EXPERIMENTAL

PGT121.414.LS

Intervention Type DRUG

Administered SC in the thigh

VRC07-523LS

Intervention Type DRUG

Administered SC in the thigh

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PGT121.414.LS

Administered SC in the thigh

Intervention Type DRUG

VRC07-523LS

Administered SC in the thigh

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Birthing parent is of legal age or circumstance to provide independent informed consent and is willing and able to provide written informed consent for themselves and permission for their infant's participation in this study.
* Birthing parent has confirmed HIV-1 infection based on positive test results from two samples collected from two separate blood collection tubes.
* Infant was singleton or twin.
* Infant's gestational age at birth was at least 36 weeks.
* At birth, infant's weight was at least 2 kg.
* At entry, infant is less than 72 hours of age and is anticipated to receive study product within 72 hours after birth.
* At screening, infant has the following laboratory test results:

* Hemoglobin, normal or grade 1 (≥13 g/dL or ≥8.05 mmol/L)
* Platelets, normal or grade 1 (≥100,000 cells/mm3 or ≥100.000 x10\^9 cells/L)
* Absolute neutrophil count (ANC), normal or grade 1

1. ≤24 hours old (≥4,000 cells/mm3 or ≥4.000 x10\^9 cells/L)
2. \>24 hours old (≥1,250 cells/mm3 or ≥1.250 x10\^9 cells/L)
* Alanine transaminase (ALT), normal (\<1.25 x ULN)
* At entry, infant is generally healthy as determined by the site investigator based on review of all available medical history information and physical examination findings.
* Cohorts 1 and 2, Strata BF only: At entry, infant is breastfeeding or the birthing parent has indicated an intention to initiate breastfeeding.
* Cohorts 1 and 2, Strata FF, only: At entry, infant is not breastfeeding and the birthing parent has indicated no intention to breastfeed.
* At entry, infant is at increased risk of HIV acquisition.

Cohorts 1 and 2, Strata FF only:

* Birthing parent had acute HIV during this pregnancy; or
* Birthing parent with detectable viral replication (plasma HIV RNA results at least 50 copies/mL) during pregnancy who did not have confirmed viral suppression, defined as at least two consecutive plasma HIV RNA results less than 50 copies/mL from specimens obtained at least four weeks apart with the latest result within four weeks prior to delivery; or
* Birthing parent not receiving appropriate ART for at least two weeks, with any part of the two-week period occurring within four weeks prior to delivery, based on birthing parent's report or available medical records.

Cohorts 1 and 2, BF only:

* Per birthing parent's report, intends to breastfeed

Exclusion Criteria

* Birthing parent has received any investigational product during this pregnancy.
* Infant has received any active or passive HIV immunotherapy or any investigational product.
* At entry, infant with a documented positive HIV Nucleic Acid Test (NAT) result.
* Birthing parent or infant has any condition that, in the opinion of the site investigator or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Maximum Eligible Age

72 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Coleen Cunningham

Role: STUDY_CHAIR

University of California, Irvine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.